EU Will not use J&J COVID shots from time of US contamination Problem

On Friday, European regulators of the pharmaceuticals sector announced that batches of the COVID-19 COVID produced to the area for Johnson & Johnson will not be used as a precaution when the contamination problems were disclosed to a US manufacturing plant.

It was not stated by EMA that it involved millions of doses, but Reuters reported that J&J had to reach a target of 55 million to Europe by the end of June. The European Medicines Agency (EMA) said that it involved millions of doses.

Reuters enquiries were not immediately answered by J&J.

EMA stated it had knowledge of a batch of J&J's active ingredient. COVID-19 vaccine had been infected by Maryland-owned Emergent Biosolutions material in April.

The U.S. authorities stopped manufacturing the J&J vaccine on-site, and J&J became responsible for plant production.

The United States Food and Drug Administration is ready to approve around 10 million doses of the plant-based vaccine, CNN said on Friday.

The mistake in April concerned components of the COVID-19 vaccine from AstraZeneca that were also manufactured in the factory and contaminated by a J&J batch made by its Janssen factory.

Batches of the released vaccine in the region were not harmed by cross-contamination based on the information; EMA claimed the load was not meant for the European Union.

Post a Comment

Please do not enter any spam link in the comment box.